Crunkhorn S. Anticancer drugs: Redesigning kinase inhibitors. February 2008. Nature Revs Drug Discovery 7:120-121 doi 10.1038/nrd2524 [7]
nih.gov
ncbi.nlm.nih.gov
Fernández A, Scott R. Dehydron: a structurally encoded signal for protein interaction. Biophys J. 2003 Sep;85(3):1914-28. PMID 12944304[2]
Fernández A, Scott R. Adherence of packing defects in soluble proteins. Phys Rev Lett. 2003 91(1):018102. PMID 12906578[3]
Fernández A. Epistructural tension promotes protein associations. Phys Rev Lett. 2012 May 4;108(18):188102. PMID 22681121[5]
Demetri G. D. Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.2007 Dec 3; J Clin Invest. 117(12):3650–3653. doi 10.1172/JCI34252 [9]
Boyd J. for Rice University News and Media. Drug design: New book introduces fresh approach. 28 April 2010 [8]Archiviato il 1º settembre 2016 in Internet Archive.
uchicago.edu
www-news.uchicago.edu
Koppes S. for University of Chicago News Office. Discovery of new sticky force that binds proteins could lead to better drug design. 2 July 2003 [4]
warf.org
Wisconsin Alumni Research Foundation, Invention: Treating Heart Failure by Inhibiting Myosin Interaction with a Regulatory Myosin Binding Protein (US patent No. 9,051,387), Inventors: Richard L. Moss and Ariel Fernandez [11]Archiviato il 10 dicembre 2015 in Internet Archive.
Boyd J. for Rice University News and Media. Drug design: New book introduces fresh approach. 28 April 2010 [8]Archiviato il 1º settembre 2016 in Internet Archive.
Wisconsin Alumni Research Foundation, Invention: Treating Heart Failure by Inhibiting Myosin Interaction with a Regulatory Myosin Binding Protein (US patent No. 9,051,387), Inventors: Richard L. Moss and Ariel Fernandez [11]Archiviato il 10 dicembre 2015 in Internet Archive.